BioCryst Pharmaceuticals Inc (BCRX: Quote) Tuesday released positive results from the extension phase of its randomized Phase 2b trial of ulodesine added to allopurinol in patients with gout, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.
The pharmaceutical company engaged in the design, optimization and development of novel small molecule drugs, revealed that the results of the 52-week, blinded Phase 2b safety extension trial confirm that ulodesine continues to be generally safe and well-tolerated in gout patients who inadequately responded to allopurinol alone, many of which had multiple co-morbidities. No clinical adverse event signals were observed that distinguished ulodesine from placebo, either by type or by rate at the doses tested.
Ulodesine is a novel enzyme inhibitor with the potential for once-a-day oral dosing suitable for chronic administration to treat gout. It acts upstream of xanthine oxidase (XO) in the purine metabolism pathway to reduce new formation of uric acid in patients with gout.
by RTT Staff Writer
For comments and feedback: email@example.com